Ocular Therapeutix (OCUL) Misses Q4 EPS by 5c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.35), $0.05 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $14.8 million versus the consensus estimate of $15.87 million.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Ocular Therapeutix (OCUL) PT Raised to $25 at H.C. Wainwright
• Qualcomm investor day to detail data center plans Wednesday
• Morgan Stanley upgrades CDW on stronger AI-driven server demand